ASH Conference Coverage
Filter News By:
Featured Articles
(BioPharma Dive) Dec 5, 2018 - Like many a medical meeting, ASH showcased data that — while promising — also offers as many questions as answers. With another American Society of Hematology meeting in the books, the industry can take a minute to appreciate the notable advances seen in San Diego earlier this week. A new...
Read Article
(BioPharma Dive) Dec 5, 2018 - In drugmakers' quest to coax immune cells to attack cancer, two might turn out to be better than one. Recent advances in cancer therapeutics have centered on the might of the body's defenders to recognize and kill tumor cells. Seeking to help the immune system "see" cancers, researchers have turned to...
Read Article
Latest Articles
December 10, 2018
December 07, 2018
December 06, 2018
December 06, 2018
December 06, 2018
December 04, 2018
December 04, 2018
December 04, 2018
View More
News Commentary
There is no ASH Conference Coverage commentary.

OBR Green
There are no ASH Conference Coverage OBR Green articles.
OBR Blog
As the ASH Annual Meeting concludes, the late-breaking abstracts are always of great interest. We take a brief look at... Read more
December 04, 2018
As the 2018 American Society of Hematology (ASH) Annual Meeting continues, we focus on two studies that have the... Read more
December 04, 2018

OBR Tweets

Jan 15
Dean Gesme, MD: C-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play a significant role… https://t.co/FPThNu4aTT

Jan 14
Howard Sandler, MD, MS, FASTRO: Radiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit… https://t.co/pGbHsJJAbs

Jan 14
Tomasz M. Beer, MD: Hot flashes are a common consequence of hormonal therapy for prostate cancer and strategies to… https://t.co/owVbzC4Sex

Jan 13
William McGivney, PhD: In Oncology, drug/biologic development is clearly in a world of orphan diseases. The FDA def… https://t.co/LXXvSjOK2x

Jan 07
H. Jack West, MD: Perhaps a bit surprising for pembro, which has had the luck or efficacy to usually be just a shad… https://t.co/bTjrJlJQwv

Dec 23
Debu Tripathy, MD: Trastuzumab deruxtecan (Enhertu), a HER2-targeting antibody drug conjugate, will represent an im… https://t.co/1x3NMQ6ZkN

Dec 16
Gwen Nichols, MD, @DrGwenNichols of @LLSusa regarding the collaboration between the Leukemia and Lymphoma Society a… https://t.co/mhmBcEyIPo

Dec 16
Andre Goy, MD, @AndreGoyMD of @JTCancerCenter @HackensackUMC regarding the ZUMA-2 study investigating anti-CD19 CAR… https://t.co/3D4ynHF64R

Dec 16
Daniel Pollyea, MD,@DanPollyea of @CUCancerCenter discusses prognostic factors in acute myeloid leukemia (AML) pati… https://t.co/rzlQEK9pie

Dec 16
Jae H. Park, MD, of @sloan_kettering on the factors associated with improved survival after CD19 CAR-T cell therapy… https://t.co/eYwzIQiW3n